Asia Pacific Vaccine Contract Manufacturing Market Size & Outlook
Asia Pacific vaccine contract manufacturing market, 2018-2030 (US$M)
Related Markets
Asia Pacific vaccine contract manufacturing market highlights
- The Asia Pacific vaccine contract manufacturing market generated a revenue of USD 1,261.0 million in 2023.
- The market is expected to grow at a CAGR of 6.7% from 2024 to 2030.
- In terms of segment, attenuated vaccine was the largest revenue generating vaccine type in 2023.
- DNA Vaccines is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 1,261.0 million |
| Market revenue in 2030 | USD 1,981.3 million |
| Growth rate | 6.7% (CAGR from 2023 to 2030) |
| Largest segment | Attenuated vaccine |
| Fastest growing segment | DNA Vaccines |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines |
| Key market players worldwide | Lonza Group Ltd, FUJIFILM Holdings Corp, Merck KGaA, Catalent Inc, Icon PLC, Syngene, Curia, Ajinomoto Co Inc, IDT Biologika |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 29.8% of the global vaccine contract manufacturing market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,981.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Vaccine Contract Manufacturing Market Scope
Vaccine Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific vaccine contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine contract manufacturing market will help companies and investors design strategic landscapes.
Attenuated vaccine was the largest segment with a revenue share of 29.97% in 2023. Horizon Databook has segmented the Asia Pacific vaccine contract manufacturing market based on attenuated vaccine, inactivated vaccine, subunit vaccines, toxoid vaccines, dna vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
The Asia Pacific vaccine contract manufacturing market is expected to grow at a lucrative pace over the forecast period. This can be attributed to favorable regulatory changes, improving infrastructure, and the presence of a large number of potential study subjects.
Growing R&D costs have compelled many U.S. biopharma companies to consider outsourcing vaccine development to Asia Pacific countries, where a large number of players offer low-cost production facilities & labor.
Reasons to subscribe to Asia Pacific vaccine contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific vaccine contract manufacturing market databook
-
Our clientele includes a mix of vaccine contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific vaccine contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific vaccine contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific vaccine contract manufacturing market size, by country, 2018-2030 (US$M)
Asia Pacific Vaccine Contract Manufacturing Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
